

certified that this rule, when promulgated, will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

The FAA's authority to issue rules regarding aviation safety is found in Title 49 of the United States Code. Subtitle I, Section 106 describes the authority of the FAA Administrator. Subtitle VII, Aviation Programs, describes in more detail the scope of the agency's authority.

This rulemaking is promulgated under the authority described in Subtitle VII, Part A, Subpart I, Section 40103. Under that section, the FAA is charged with prescribing regulations to assign the use of the airspace necessary to ensure the safety of aircraft and the efficient use of airspace. This regulation is within the scope of that authority as it amends existing VOR Federal airways in the NAS.

### Environmental Review

The FAA has determined that this action qualifies for categorical exclusion under the National Environmental Policy Act in accordance with 311a, FAA Order 1050.1E, "Environmental Impacts: Policies and Procedures." This airspace action is not expected to cause any potentially significant environmental impacts, and no extraordinary circumstances exist that warrant preparation of an environmental assessment.

### List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

### Adoption of the Amendment

In consideration of the foregoing, the Federal Aviation Administration amends 14 CFR part 71 as follows:

## PART 71—DESIGNATION OF CLASS A, B, C, D, AND E AIRSPACE AREAS; AIR TRAFFIC SERVICE ROUTES; AND REPORTING POINTS

- 1. The authority citation for part 71 continues to read as follows:

**Authority:** 49 U.S.C. 106(g), 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959–1963 Comp., p. 389.

### § 71.1 [Amended]

- 2. The incorporation by reference in 14 CFR 71.1 of FAA Order 7400.9W, Airspace Designations and Reporting Points, signed August 8, 2012, and effective September 15, 2012, is amended as follows:

*Paragraph 6010 VOR Federal airways.*

\* \* \* \* \*

### V–68

From Montrose, CO; Cones, CO; Dove Creek, CO; Cortez, CO; Rattlesnake, NM; INT Rattlesnake 128° and Albuquerque, NM, 345° radials; Albuquerque; INT Albuquerque 120° and Corona, NM, 311° radials; Corona; 41 miles 85 MSL, Chisum, NM; Hobbs, NM; Midland, TX; San Angelo, TX; Junction, TX; Center Point, TX; San Antonio, TX; INT San Antonio 064° and Industry, TX, 267° radials; Industry; INT Industry 101° and Hobby, TX, 289° radials; to Hobby.

\* \* \* \* \*

### V–76

From Lubbock, TX; INT Lubbock 188° and Big Spring, TX, 286° radials; Big Spring; San Angelo, TX; Llano, TX; Centex, TX; Industry, TX; INT Industry 101° and Hobby, TX, 289° radials; to Hobby.

\* \* \* \* \*

### V–194

From Cedar Creek, TX; College Station, TX; INT College Station 151° and Hobby, TX, 289° radials; Hobby; Sabine Pass, TX; Lafayette, LA; Baton Rouge, LA; McComb, MS; INT McComb 055° and Meridian, MS; 221° radials; Meridian. From Liberty, NC; Raleigh-Durham, NC; Tar River, NC; Cofield, NC; to INT Cofield 077° and Norfolk, VA, 209° radials.

\* \* \* \* \*

### V–548

From Hobby, TX; INT Hobby 289° and College Station, TX, 151° radials; College Station; INT College Station 307° and Waco, TX, 173° radials; to Waco.

Issued in Washington, DC, March 26, 2013.

**Gary A. Norek,**

*Manager, Airspace Policy and ATC Procedures Group.*

[FR Doc. 2013–07472 Filed 4–2–13; 8:45 am]

**BILLING CODE 4910–13–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### 21 CFR Parts 510, 522, and 558

[Docket No. FDA–2013–N–0002]

### New Animal Drugs; Enrofloxacin; Tilmicosin; Tylosin

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule, technical amendment.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the

animal drug regulations to reflect approval actions for new animal drug applications and abbreviated new animal drug applications during February 2013. FDA is also informing the public of the availability of summaries the basis of approval and of environmental review documents, where applicable.

**DATES:** This rule is effective April 3, 2013.

### FOR FURTHER INFORMATION CONTACT:

George K. Haibel, Center for Veterinary Medicine (HFV–6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240–276–9019, [george.haibel@fda.hhs.gov](mailto:george.haibel@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** FDA is amending the animal drug regulations to reflect approval actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during February 2013, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the Center for Veterinary Medicine (CVM) FOIA Electronic Reading Room: <http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/CVMFOIAElectronicReadingRoom/default.htm>.

In addition, the animal drug regulations are being amended at 21 CFR 510.600 to correct the spelling of a street name in the sponsor's address, and at 21 CFR 558.618 to clarify the dosage of tilmicosin phosphate in medicated feeds for beef and non-lactating dairy cattle.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

TABLE 1—ORIGINAL AND SUPPLEMENTAL NADAS AND ANADAS APPROVED DURING FEBRUARY 2013

NADA/ ANADA	Sponsor	New animal drug product name	Action	21 CFR section	FOIA Sum- mary	NEPA Review
200–495	Norbrook Laboratories, Ltd., Station Works, Newry BT35 6JP, Northern Ireland.	ENROFLOX 100 (enrofloxacin) Injectable Solution.	Original approval as a generic copy of NADA 141–068.	522.812	yes .....	CE <sup>1</sup>
200–509	Huvepharma AD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria.	TILMOVET 90 (tilmicosin phosphate) Type A medi- cated article.	Original approval as a generic copy of NADA 141–064.	558.618	yes .....	CE <sup>1</sup>
200–531	Huvepharma AD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria.	TYLOVET 100 (tylosin phos- phate) and RUMENSIN (monensin) Type A medi- cated articles.	Original approval as a generic copy of NADA 104–646.	558.355	yes .....	CE <sup>1</sup>

<sup>1</sup> The Agency has determined under 21 CFR 25.33 that this action is categorically excluded (CE) from the requirement to submit an Environmental Assessment or an Environmental Impact Statement because it is of a type that does not individually or cumulatively have a significant effect on the human environment.

## List of Subjects

### 21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

### 21 CFR Part 522

Animal drugs.

### 21 CFR Part 558

Animal drugs, Animal feed.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 522, and 558 are amended as follows:

## PART 510—NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:** 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

### § 510.600 [Amended]

■ 2. In § 510.600, in the table in paragraph (c)(1), in the entry for “Huvepharma AD”, remove “Haitov” and in its place add “Haytov”; and in the table in paragraph (c)(2), in the entry for “016592”, remove “Haitov” and in its place add “Haytov”.

## PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

■ 3. The authority citation for 21 CFR part 522 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

■ 4. In § 522.812, revise paragraphs (b) and (e)(3)(ii); and add introductory text to paragraph (e)(2) to read as follows:

### § 522.812 Enrofloxacin.

\* \* \* \* \*

(b) *Sponsors.* See sponsor numbers in § 510.600(c) of this chapter:

(1) No. 000859 for use of products described in paragraph (a) as in paragraph (e) of this section; and

(2) No. 055529 for use of product described in paragraph (a)(2) as in paragraphs (e)(2)(i)(B), (e)(2)(ii)(B), (e)(2)(iii), (e)(3)(i), and (e)(3)(iii) of this section.

\* \* \* \* \*

(e) \* \* \*

(2) *Cattle.* Use the product described in paragraph (a)(2) of this section as follows:

\* \* \* \* \*

(3) \* \* \*

(ii) *Indications for use*—(A) For the treatment and control of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Haemophilus parasuis*, *Streptococcus suis*, *Bordetella bronchiseptica*, and *Mycoplasma hyopneumoniae*.

(B) For the treatment and control of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Haemophilus parasuis*, and *Streptococcus suis*.

\* \* \* \* \*

## PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

■ 5. The authority citation for 21 CFR part 558 continues to read as follows:

**Authority:** 21 U.S.C. 360b, 371.

■ 6. In § 558.355, remove and reserve paragraph (f)(3)(ix); and in paragraphs (f)(3)(ii)(b) and (f)(3)(xii)(b), add a new last sentence to read as follows:

### § 558.355 Monensin.

\* \* \* \* \*

(f) \* \* \*

(3) \* \* \*

(ii) \* \* \*

(b) \* \* \* Tylosin provided by Nos. 000986 and 016592 in § 510.600(c) of this chapter.

\* \* \* \* \*

(xii) \* \* \*

(b) \* \* \* Tylosin provided by Nos. 000986 and 016592 in § 510.600(c) of this chapter.

\* \* \* \* \*

### § 558.618 [Amended]

■ 7. Amend § 558.618 as follows:

■ a. In paragraph (b), remove “No. 000986” and in its place add “Nos. 000986 and 016592”;

■ b. In the table in paragraph (e)(1)(i), in the “Sponsor” column, add “, 016592” after “000986”;

■ c. In the table in paragraph (e)(1)(ii), in the “Sponsor” column, remove “000986”;

■ d. In the table in paragraph (e)(2)(i), in the “Limitations” column, in the first sentence, remove “12.5 milligrams/kilogram/head/day” and in its place add “12.5 mg tilmicosin/kg of bodyweight/day”; and

■ e. In the table in paragraphs (e)(2)(ii) and (e)(2)(iii), in the “Limitations” column, in the first sentence, remove “12.5 milligrams tilmicosin/kilogram/head/day” and in its place add “12.5 mg tilmicosin/kg of bodyweight/day”.

Dated: March 26, 2013.

**Bernadette Dunham,**

*Director, Center for Veterinary Medicine.*

[FR Doc. 2013–07571 Filed 4–2–13; 8:45 am]

**BILLING CODE 4160–01–P**